NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Portfolio Pulse from Lisa Levin
Insiders at Alzamend Neuro, Chimerix, and NetSol Technologies have recently purchased shares in their respective companies. Alzamend Neuro's CFO acquired 53,000 shares at an average price of $0.19, following the company's submission of an investigational new drug application to the FDA. Chimerix's Director bought 20,000 shares at an average price of $0.98 after the company posted a narrower-than-expected Q2 loss. NetSol Technologies' CEO purchased 10,000 shares at an average price of $1.88, despite the company posting a wider loss for Q4.
September 27, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alzamend Neuro's CFO purchased 53,000 shares following the company's submission of a new drug application to the FDA.
The CFO's purchase of shares indicates confidence in the company's prospects, particularly following the submission of a new drug application to the FDA. This could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Chimerix's Director purchased 20,000 shares after the company posted a narrower-than-expected Q2 loss.
The Director's purchase of shares after a narrower-than-expected Q2 loss indicates confidence in the company's financial recovery. This could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
NetSol Technologies' CEO purchased 10,000 shares despite the company posting a wider loss for Q4.
The CEO's purchase of shares despite a wider Q4 loss indicates confidence in the company's future prospects. This could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 100